HC Wainwright & Co. : The Curis (CRIS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $26.00.
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
Curis Analyst Ratings
Canto Fitzgerald: Confirmed Curis (CRIS.US) increase in holdings rating.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Truist Financial Releases a Buy Rating on Curis (CRIS)
Curis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
Curis Buy Rating Affirmed on Strong Earnings and Promising Emavusertib Trials
Curis Inc. Insiders Hold Steady: No New Trades Signal Confidence or Complacency?
Curis (CRIS) Gets a Buy From Truist Financial
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
Curis Analyst Ratings
Positive Buy Rating for Curis Stock Driven by Emavusertib's Clinical Promise and Revenue Potential
Truist Securities Initiates Coverage On Curis With Buy Rating, Announces Price Target of $26
Curis Analyst Ratings
Analysts Conflicted on These Healthcare Names: Curis (CRIS), Trevi Therapeutics (TRVI) and Prothena (PRTA)
HC Wainwright & Co. Reiterates Buy on Curis, Raises Price Target to $51
Curis Analyst Ratings
Buy Rating for Curis (CRIS) Amidst Reverse Stock Split and Revised Launch Estimates for Key Product, Emavusertib
No Data